OsteoCentric
1 known investors
OsteoCentric Technologies develops UnifiMI, a patented implant-to-bone interface and thread-form design intended to preserve bone architecture during implant insertion and provide immediate primary stability. The technology targets orthopedic and dental implant applications to accelerate patient recovery.
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does OsteoCentric do?
- OsteoCentric Technologies develops UnifiMI, a patented implant-to-bone interface and thread-form design intended to preserve bone architecture during implant insertion and provide immediate primary stability. The technology targets orthopedic and dental implant applications to accelerate patient recovery.
- Who are OsteoCentric's investors?
- OsteoCentric's investors include JStar Capital Investments.